Results from a Phase I/II trial of the investigational compound lenvatinib (E7080), a multi-targeted, kinase inhibitor, in people with advanced hepatocellular cancer have been presented at the ESMO 2012 Congress (European Society for Medical Oncology) taking place on Friday 28 September - Tuesday 2 October. Two other studies were presented, reporting the results of lenvatinib in the treatment of recurrent glioblastoma (the most common type of brain cancer which is almost universally fatal) and lenvatinib in combination with everolimus in metastatic renal cell carcinoma.
The purpose of this analysis from the phase II trial was to investigate the effects of tasquinimod on selected biomarkers to confirm preclinical findings on the mechanism of action.
Rarely, renal cell carcinomas may also contain evidence of macroscopic fat.
Matt Cardle on why he fights for thousands of children struck by a rare and deadly disease
Researchers at the University of California, San Diego School of Medicine have found that recovery from an emerging, minimally invasive surgical technique called Laparo-Endoscopic Single-Site Surgery (LESS) was less painful for kidney cancer patients than traditional laparoscopic surgery.
The FDA said today it has approved regorafenib (Stivarga) as a new treatment in the U.S. for patients with colorectal cancer that has spread after treatment with prior therapies.
This annual meeting attracts an audience of hundreds of medical practitioners and scientists from the US, Asia, Europe, and Latin America.
A comprehensive analysis of prognostic factors.
The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this research grant is to fund physicians during the transition from a fellowship program to a faculty appointment.
The majority of the responses seen with BMS-936558 lasted longer than one year. In addition, these anti-PD-1 antibodies managed to shrink away large metastatic tumors like lung and kidney, which are typically pretty resistant to therapy.
|NeonCRM by Neon One|